Covaxin Safe For Children Aged 2-18, Finishes Clinical Trials: BBIL

Bharat Biotech International Limited (BBIL) announced that after phase II/III trials, Covaxin can safely be administered to children between ages two and 18. Reportedly, the phases II/III studies were conducted to evaluate the safety, reactogenicity and immunogenicity of the vaccine in healthy children and adolescents. "We have now achieved our goal of developing safe and efficacious Covid-19 vaccine for adults and children," said Dr Krishna Ella, Chairman and MD, BBIL.